Abstract:We aim at investigating the association between subclinical autoimmunity and immune-related adverse events (irAEs) in a cohort of patients treated by immune checkpoint inhibitors for solid metastatic cancer. In the context of an oncology/rheumatology outpatient clinic, we evaluated patients treated with anti-PD-1 or anti-PD-L1. Before treatment, each patient underwent a physical evaluation and a blood sample to identify the presence of a set of autoantibodies. Indeed, all the patients were followed during treatment to identify irAEs and to assess the association with autoantibodies. Fifty-one patients (M/F 16/35; median age 70 years, IQR 16.5) were evaluated; 34.8% of patients showed ANA positivity, 6.5% ENA positivity (anti-SSA), 4.3% Ratest positivity, and 2.1% (one patient) ACPA positivity. During a median period of 21 months (IQR 38.75), 39.2% of patients developed irAEs. Musculo-skeletal manifestations, in particular arthritis, were the most frequent. We found a significant association between the positivity for ANA and the development of irAES ( p = 0.03, RR 2.01, 95% CI 1.03–3.92). Furthermore, the progression-free survival was significantly longer in patients developing irAEs compared to those who are not experiencing these events ( p = 0.007). This study underlines the potential role of ANA positivity as a predictive biomarker for the development of irAEs.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the association between sub - clinical autoimmune status and immune - related adverse events (irAEs) that occur during treatment with immune checkpoint inhibitors (ICIs). Specifically, the study aims to evaluate whether antinuclear antibody (ANA) positivity can be used as a biomarker to predict the development of irAEs in patients with solid metastatic cancers treated with ICIs. ### Research Background - **Immune checkpoint inhibitors (ICIs)**: In recent years, ICIs have become a major treatment method in oncology, significantly improving the prognosis of patients. - **Immune - related adverse events (irAEs)**: The use of ICIs has led to a series of immune - related side effects, which may affect any organ system, ranging from mild self - limiting diseases to severe life - threatening clinical manifestations. - **Sub - clinical autoimmunity**: This state refers to an autoimmune disease in which autoantibodies are present in the blood but there are no clinical symptoms. Treatment with ICIs may trigger this sub - clinical autoimmunity, leading to the occurrence of irAEs. ### Research Objectives - **Primary objective**: To investigate the association between sub - clinical autoimmune status and the development of irAEs. - **Specific objectives**: - To evaluate the autoantibody status of patients before ICIs treatment. - To track whether patients develop irAEs during treatment. - To analyze the relationship between ANA positivity and the occurrence of irAEs. - To explore the impact of ANA positivity on progression - free survival (PFS). ### Methods - **Study design**: A single - center prospective cohort study. - **Patient selection**: Include patients with solid metastatic cancers who are receiving PD - 1 or PD - L1 inhibitor treatment. - **Baseline assessment**: Conduct physical examinations and blood sample tests before treatment, including ANA, anti - dsDNA, rheumatoid factor (RF), anti - cyclic citrullinated protein antibody (ACPA) and extractable nuclear antigen antibody (ENA). - **Follow - up**: Regularly follow - up patients, record the occurrence of irAEs, and evaluate PFS and overall survival (OS). ### Results - **Patient characteristics**: A total of 51 patients were included, with a median age of 70 years, 16 males and 35 females. - **Autoantibody positive rates**: - The ANA positive rate was 34.8%. - The ENA positive rate was 6.5% (all were anti - SSA antibodies). - The Ratest positive rate was 4.3%. - The ACPA positive rate was 2.1%. - **irAEs incidence**: 39.2% of patients developed irAEs during a median follow - up period of 21 months, and the most common irAEs was arthritis. - **Relationship between ANA positivity and irAEs**: - Patients with ANA positivity had a significantly higher risk of developing irAEs than those with ANA negativity (p = 0.03, relative risk RR = 2.01, 95% CI 1.03–3.92). - The PFS of patients who developed irAEs was significantly longer than that of patients who did not develop irAEs (p = 0.007). ### Discussion - **ANA positivity as a biomarker**: The study shows that ANA positivity may be a potential biomarker for predicting the occurrence of irAEs. - **irAEs and treatment efficacy**: Patients who developed irAEs had a longer PFS, suggesting that irAEs may be a sign of effective treatment. - **Study limitations**: The study sample size was small, and the heterogeneity of cancer types and stages may affect the statistical results. ### Conclusion This study emphasizes the potential role of ANA positivity in predicting the occurrence of irAEs during ICIs treatment, providing valuable clues for further research.

Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort

Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy.

Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition

Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events

Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors

Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

The Onset of Antinuclear Antibodies (ANAs) as a Potential Risk Factor for Mortality and Morbidity in COVID-19 Patients: A Single-Center Retrospective Study

Abstract 5141: Autoantibody profiling for predictive biomarkers for immune-related adverse events and clinical benefit in rare tumors treated with anti-PD-1 therapy

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center

Baseline ANA and Anti‐Ro60/SSA Antibody as Potential Predictors for Immunogenicity and Poor EULAR Response in Adalimumab‐Treated RA Patients

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab

Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial